VANCOUVER, Feb. 12 /CNW/ - Response Biomedical Corporation (TSX: RBM,
OTCBB: RPBIF) announced that Roche Diagnostics has agreed to fund two new
projects aimed at strengthening the commercial success of the Response
cardiovascular line of products that Roche is expected to market in North
America, beginning in this quarter. Response Biomedical and Roche Diagnostics
signed a strategic partnership in June 2008 to commercialize Response's
The first project approved for funding is to complete a submission for a
CLIA-waiver for the RAMP(R) NT-proBNP assay. NT-proBNP is used in the
diagnosis of heart failure. The RAMP(R) NT-proBNP assay has been well accepted
as a rapid, accurate test to expedite this diagnosis. In an effort to expand
the availability of this system to physician's offices and smaller group
practices that are only licensed to perform simple (CLIA-waived) tests, Roche
and Response will combine efforts to complete a clinical trial to support
CLIA-waived status for the RAMP(R) NT-proBNP assay. The trial is expected to
be completed and the CLIA-waiver submission made to the FDA in 2009.
"The availability of a CLIA-waived NT-proBNP test will open the doors to
the use of the Cardiac 200 system in small practices and physician's offices,
and will complement current CLIA-waived Roche offerings for blood glucose and
oral anticoagulation monitoring," said Bernd Schnakenberg, Head of
Decentralized Solutions, Roche Professional Diagnostics.
The next project Response will undertake, is a next-generation Troponin I
(TnI) assay development. Troponin I is a critical part of the diagnosis of
heart attacks or acute myocardial infarction, especially for the more than 50
percent of cases where an electrocardiogram is inconclusive. The development
of the improved RAMP(R) TnI test will re-align the results obtained to more
closely reflect those obtained on the most commonly used central laboratory
"We are very excited about expanding our collaboration with Roche
Diagnostics," said S. Wayne Kay, Chief Executive Officer, Response Biomedical.
"Roche is one of the largest in vitro diagnostics companies in the world, and
we could not ask for a stronger partner to commercialize our cardiovascular
product line. We have already begun work on these two important projects and
Roche's support will allow us the ability to focus key resources to advance
the cardiovascular product line while conserving cash outlays by Response."
The RAMP(R) cardiovascular product line includes NT-proBNP, Troponin I,
CK-MB and Myoglobin tests.
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site
diagnostic tests for use with its RAMP(R) Platform for clinical and
environmental applications. RAMP(R) represents a new paradigm in diagnostics
that provides high sensitivity and reliable information in minutes. It is
ideally suited to both point-of-care testing and laboratory use. The RAMP(R)
system consists of a Reader and single-use disposable test cartridges, and has
the potential to be adapted to more than 250 medical and non-medical tests
currently performed in laboratories. RAMP(R) clinical tests are commercially
available for the early detection of heart attack, congestive heart failure
In the non-clinical market, RAMP(R) Tests are currently provided for the
environmental detection of West Nile Virus, and Biodefense applications
including the rapid on-site detection of anthrax, smallpox, ricin and
botulinum toxin. Several other product applications are under development.
Response has achieved CE Marking for its Reader and clinical tests and its
Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.
The RAMP(R) Influenza A/B Assay and RAMP 200 reader are not yet licensed for
clinical use in Canada.
Response Biomedical is a publicly traded company, listed on the TSX under
the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol
"RPBIF". For further information, please visit the Company's website at
Statements contained in this press release relating to future results,
events or developments, for example, statements containing the words
"believes," "may," "could", "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects", "goal" and similar expressions, are
"forward-looking statements" or "forward-looking information" under applicable
United States and Canadian securities laws. Forward-looking statements or
information may involve, but are not limited to, comments with respect to our
planned activities, business plan and strategies and their future
implementation, and our expectations for our financial condition and the
results of, or outlook for, our business operations generally. Forward-looking
statements or information are subject to the related assumptions made by us
and involve known and unknown risks, uncertainties and other factors that may
cause actual results, events or developments to be materially different from
those expressed or implied by such statements or information.
Many of such risks, uncertainties and other factors form part of our
underlying assumptions, and include, among other things, financial risks that
would affect our operations such as our available working capital and cash
flows and whether and for how long available funds will be sufficient to fund
our operations and our ability to raise additional capital as and when needed;
our need for substantial additional funding to conduct research and
development and commercialization activities; our ability to establish, and
our dependence upon, relationships with strategic alliance partners to develop
and commercialize products; technological changes that impact our existing
products or our ability to develop and commercialize our products; our ability
to obtain and enforce timely patent and other intellectual property protection
for our technology and products; liability for patent, product liability and
other claims asserted against us; commercialization limitations imposed by
patents owned or controlled by third parties; our ability to retain, and our
reliance upon, third party suppliers, manufacturers, distributors and alliance
partners; our ability to effectively and efficiently manage the planned growth
of our operations; our ability to profitably sell our products at prices that
would be acceptable to third-party reimbursement programs; competition
including competition from others with significantly more resources; market
acceptance of our products and the size of our markets; changes in business
strategy or development plans; changes in, or the failure to comply with,
governmental regulations; and other factors referenced in our annual report,
our Annual Information Form (AIF) (Form 40-F in the U.S.) and other filings
with Canadian and United States securities regulatory authorities.
Given these uncertainties, assumptions and risks, readers are cautioned
not to place undue reliance on such forward-looking statements or information.
We disclaim any obligation to update, or to publicly announce any revisions
to, any such statements or information to reflect future results, events or
developments, except as required by law.
For further information:
For further information: Response Biomedical Contacts: Bill Wickson,
Director, Investor Relations, Response Biomedical Corporation, Tel (604)
456-6073, Email: firstname.lastname@example.org